Catalent Inc (NYSE:CTLT) insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Catalent Inc (CTLT) traded up $0.04 during trading on Thursday, hitting $40.06. The stock had a trading volume of 887,052 shares, compared to its average volume of 908,550. The firm has a market cap of $5,320.00, a price-to-earnings ratio of 27.65, a P/E/G ratio of 2.54 and a beta of 1.41. Catalent Inc has a 52 week low of $25.51 and a 52 week high of $43.39. The company has a debt-to-equity ratio of 2.01, a current ratio of 2.91 and a quick ratio of 2.49.

Catalent (NYSE:CTLT) last posted its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million during the quarter, compared to analyst estimates of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.16 EPS. equities research analysts expect that Catalent Inc will post 1.46 EPS for the current fiscal year.

Several large investors have recently added to or reduced their stakes in the company. Advisor Group Inc. lifted its holdings in shares of Catalent by 1.3% during the 2nd quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock valued at $180,000 after purchasing an additional 65 shares in the last quarter. Stifel Financial Corp lifted its holdings in shares of Catalent by 0.9% during the 2nd quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock valued at $377,000 after purchasing an additional 96 shares in the last quarter. Aperio Group LLC lifted its holdings in shares of Catalent by 0.8% during the 2nd quarter. Aperio Group LLC now owns 23,088 shares of the company’s stock valued at $810,000 after purchasing an additional 190 shares in the last quarter. People s United Financial Inc. lifted its holdings in shares of Catalent by 1.9% during the 2nd quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock valued at $665,000 after purchasing an additional 356 shares in the last quarter. Finally, Commerce Bank lifted its holdings in shares of Catalent by 3.3% during the 2nd quarter. Commerce Bank now owns 17,315 shares of the company’s stock valued at $608,000 after purchasing an additional 555 shares in the last quarter. Institutional investors and hedge funds own 99.49% of the company’s stock.

A number of analysts recently commented on the company. BidaskClub upgraded Catalent from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Wells Fargo & Company lifted their price objective on Catalent from $39.00 to $43.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 20th. Bank of America reiterated a “buy” rating and issued a $45.00 price objective (up from $40.00) on shares of Catalent in a research report on Wednesday, September 20th. Royal Bank of Canada assumed coverage on Catalent in a research report on Wednesday. They issued an “outperform” rating and a $46.00 price objective for the company. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Catalent currently has an average rating of “Buy” and an average price target of $44.44.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/catalent-inc-ctlt-insider-john-r-chiminski-sells-181458-shares-of-stock/1764517.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with Analyst Ratings Network's FREE daily email newsletter.